Insulin Lispro Sanofi

Insulin lispro, the active ingredient in Insulin Lispro Sanofi, is an insulin analog presented as a clear, sterile solution for subcutaneous and intravenous administration. It rapidly lowers elevated blood glucose levels in individuals with type 1 or type 2 diabetes mellitus, providing mealtime glucose control.

GNH USA supplies Insulin Lispro Sanofi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance across global markets.

Insulin Lispro Sanofi is a rapid‑acting insulin analog used in the management of diabetes mellitus.

- Type 1 diabetes mellitus: provides mealtime insulin to control post‑prandial glucose spikes. - Type 2 diabetes mellitus: used as part of intensive insulin regimens to achieve glycemic targets. - Gestational diabetes mellitus: may be employed when rapid‑acting insulin is required under specialist supervision.

Common Side Effects: - Hypoglycemia: low blood glucose levels, especially if meals are missed or dosing is excessive. - Injection site reactions: redness, swelling, or itching at the injection site. - Weight gain: modest increase due to improved glucose utilization. - Lipodystrophy: localized changes in subcutaneous fat with repeated injections. - Localized allergic reactions: mild rash or urticaria. - Transient headache or dizziness.

Serious or Rare Side Effects: - Severe hypoglycemia requiring assistance. - Anaphylactic reaction: rapid swelling, breathing difficulty, or shock. - Hypokalemia: low potassium levels, potentially leading to cardiac arrhythmias. - Edema: swelling of extremities. - Acute allergic syndrome: serum sickness–like manifestations. - Persistent hyperglycemia despite therapy, indicating possible resistance or dosing error.

When using Insulin Lispro Sanofi, consider the following precautions: - Dose adjustment: tailor the dose based on frequent blood glucose monitoring and carbohydrate intake. - Hypoglycemia risk: educate patients on recognizing and treating low blood glucose episodes. - Renal impairment: monitor closely as reduced renal function may prolong insulin action. - Pregnancy: use only if the anticipated benefit justifies potential risk to the fetus. - Drug interactions: review concomitant medications that may potentiate or diminish insulin effects. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Insulin Lispro Sanofi may interact with several medications.

Major Interactions (Avoid): - Sulfonylureas: combined use can cause severe hypoglycemia. - Beta‑blockers: may mask typical hypoglycemia symptoms. - Glucocorticoids: can markedly reduce insulin efficacy, necessitating dose changes.

Moderate Interactions (Monitor Closely): - ACE inhibitors: may enhance insulin sensitivity, increasing hypoglycemia risk. - Thiazide diuretics: can raise blood glucose, potentially requiring higher insulin doses. - Alcohol: may cause delayed hypoglycemia, especially with binge drinking.